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Since streptozotocin (STZ)-induced diabetes is a widely used model of painful diabetic neuropathy, the aim of the present study
was to design a rational protocol to investigate whether the development of mechanical hypernociception induced by STZ
depends exclusively on hyperglycemia. Male Wistar rats (180-200 g; N = 6-7 per group) received a single intravenous injection
of STZ at three different doses (10, 20, or 40 mg/kg). Only the higher dose (40 mg/kg) induced a significant increase in blood
glucose levels, glucose tolerance and deficiency in weight gain. However, all STZ-treated rats (hyperglycemic or not) developed
persistent (for at least 20 days) and indistinguishable bilateral mechanical hypernociception that was not prevented by daily
insulin treatment (2 IU twice a day, sc). Systemic morphine (2 mg/kg) but not local (intraplantar) morphine treatment (8 μg/paw)
significantly inhibited the mechanical hypernociception induced by STZ (10 or 40 mg/kg). In addition, intraplantar injection of STZ
at doses that did not cause hyperglycemia (30, 100 or 300 μg/paw) induced ipsilateral mechanical hypernociception for at least
8 h that was inhibited by local and systemic morphine treatment (8 μg/paw or 2 mg/kg, respectively), but not by dexamethasone
(1 mg/kg, sc). The results of this study demonstrate that systemic administration of STZ induces mechanical hypernociception
that does not depend on hyperglycemia and intraplantar STZ induces mechanical sensitization of primary sensory neurons
responsive to local morphine treatment.
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Introduction
Neuropathy is the most common chronic complication
of diabetes mellitus. The prevalence of diabetic peripheral
neuropathy is about 32% in both type 1 and type 2 diabetic
subjects (1). One of the most elusive symptoms in diabetic
neuropathy is pain, characterized by mechanical and ther-
mal hyperalgesia (an increased response to a stimulus,
which is normally painful) or allodynia (pain due to a
stimulus that does not normally provoke pain), phenomena
that involve two components, i.e., nociception and percep-
tion. Since animal models do not allow discrimination of the
emotional component, the terms nociception and hyperno-
ciception are used to describe overt behavior induced by
mechanical stimulation and increased nociceptor sensitiv-
ity, respectively (2). The pathophysiology of painful diabe-
tes neuropathy is unclear, although it has been associated
with impaired peripheral nerve conduction and degenera-
tion of myelinated and unmyelinated fibers (3).
To provide information on underlying mechanisms and
to evaluate potential therapies, experimental research on
diabetic neuropathy is usually carried out using genetic or
chemically induced diabetic animal models (4). Streptozo-
tocin (STZ), an antibiotic extracted from Streptomyces
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achromogenes, is one of the chemical agents most com-
monly used to induce experimental diabetic syndrome in
mammals. It has been well defined that a systemic injec-
tion of STZ induces hyperalgesia to thermal (5-9), mechan-
ical (8-15) and chemical (8,11,16-18) noxious stimuli. STZ-
induced hyperalgesia is frequently associated with hyper-
glycemia because in some studies its development was
prevented by insulin treatment (6,7,12,14,19,20). Although
these studies suggest that STZ induces painful diabetic
neuropathy, it is important to point out that the majority of
studies evaluating STZ-induced hyperalgesia only include
animals rendered hyperglycemic. In fact, it was observed
that, in vivo, chronic perfusion of hyperglycemic solution
into the dorsal root ganglion or into a segment of the sciatic
nerve induces mechanical hyperalgesia of the same mag-
nitude as that observed after STZ treatment (21,22). How-
ever, hyperglycemia may not be the single factor involved
in STZ-induced hyperalgesia because insulin treatment
did not completely prevent it (23).
Romanosvki et al. (24) demonstrated that, although the
intraperitoneal administration of 50 mg/kg STZ induced
hyperglycemia in 40% of injected rats, 100% developed
mechanical hyperalgesia. This observation suggests, at
least in part, that mechanical hyperalgesia is not com-
pletely dependent on STZ-induced hyperglycemia.
The aim of the present study was to design a rational
protocol to determine whether systemic administration of
non-hyperglycemic doses of STZ induces hind paw me-
chanical hypernociception in the rat. Additionally, we de-
termined whether the local (intraplantar, ipl ) administra-
tion of STZ induces mechanical hypernociception.
Material and Methods
Animals
Male Wistar rats (180-200 g) were housed in a temper-
ature-controlled room, with free access to water and food.
All experiments were conducted in accordance with NIH
guidelines on the welfare of experimental animals and with
the approval of the Ethics Committee on the use of animals
of the School of Medicine of Ribeirão Preto (University of
São Paulo).
STZ treatment
After 12 h of food deprivation, rats (N = 6-7 per group)
under light anesthesia received citrate buffer (CB; 10 mM,
pH 4.5; control rats) or STZ (10, 20, or 40 mg/kg; dissolved
in CB) via the dorsal penile vein. Three days later, glyce-
mia was determined in the morning (8:00-9:00 am) in a
blood sample obtained by tail prick using a strip operated
reflectance meter (Precision Q.I.D.® Blood glucose Sen-
sor; Medisense, Inc., USA). Only rats treated intrave-
nously (iv ) with the STZ dose of 40 mg/kg developed
insulin-deficient diabetes characterized by non-fasting
blood sugar levels ≥250 mg/dL. For the experiments where
the local effect of STZ was evaluated, rats (N = 6-7 per
group) received an ipl injection of 100 μL CB or STZ (30,
100, or 300 μg/paw; dissolved in 100 μL CB). Blood glu-
cose levels were measured 8 h after ipl STZ treatment.
Glucose tolerance test
The test was conducted in the morning 20 days after iv
treatment with vehicle (CB) or STZ (10, 20 or 40 mg/kg). A
blood sample was collected from the capillary bed of the
tail tip of rats fasted for 12 h and the animals then received
an iv injection of 0.5 g/kg glucose (1 mL/200 g body
weight). Blood glucose levels were determined again 7.5,
15, 30, and 60 min after the glucose overload as described
above.
Nociceptive test: mechanical hypernociception
Mechanical hypernociception was measured at differ-
ent times after iv or ipl injection of STZ using a constant
pressure rat-paw test (25). Briefly, a constant pressure of
20 mmHg (measured using a sphygmomanometer) was
applied via a syringe piston moved by compressed air to a
15-mm2 area on the dorsal surface of the hind paw, and
discontinued when the rat presented a typical “freezing
reaction”. This reaction consists of brief apnea, concomi-
tant with retraction of the head and forepaws, and a reduc-
tion in the escape movements that animals normally make
to free themselves from the position imposed by the ex-
perimental situation. Usually, the apnea is associated with
successive waves of muscular tremor. For each animal,
the latency to the onset of the freezing reaction was meas-
ured before STZ injection (basal latency) and at different
times after STZ administration. The intensity of mechani-
cal hypernociception is reported as the reduction in the
reaction time, calculated by subtracting the value of meas-
urements after STZ from the basal latencies (25). This
mechanical constant pressure test was used in this study
because, compared with other mechanical nociceptive
paw tests, this test does not present variations in baseline
values (typically 32-34 s) and is independent of rat weight.
Reaction time was 30.2 ± 0.5 s (mean ± SEM, N = 15)
before injection of the hypernociceptive agents or after
multiple ipl injections of saline. Mechanical hypernocicep-
tion was evaluated at indicated times after iv (10, 20, or 40
mg/kg) or ipl (30, 100, or 300 μg/paw) administration of
STZ or CB (vehicle, 10 mM, pH 4.5 or 7.0, respectively). All
experiments involving the local administration of STZ and
the effect of drugs on the hypernociceptive effect of STZ
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were conducted in a double-blind manner, with the person
who injected the solutions (saline, morphine or dexameth-
asone) being different from the one who made the behav-
ioral assessment.
Paw edema measurement
Paw edema was measured by volume displacement of
an electrolyte solution (7150 plethysmometer, Ugo Basile,
Italy) 1, 3, and 5 h after the ipl administration of 10 mM CB
(pH 7.0, 100 μL) or STZ (30, 100, or 300 μg/paw, in 100 μL
CB, pH 7.0). The increase in paw volume (Δ volume) was
obtained by subtracting the paw volume measured prior to
the injection of the stimuli from the volumes at different times.
Drugs
The following drugs and reagents were used: streptozo-
tocin and dexamethasone (Sigma, USA), sodium citrate
(Merck S.A. Indústrias Farmacêuticas, Brazil), porcine NPH
insulin (Biobrás S.A., Brazil), and glucose (Carlo Erba do
Brasil S.A., Brazil). Morphine was a gift from Cristália Produtos
Químicos Farmacêuticos Ltda., Brazil (lot #10730/02).
Experimental protocol
Effects of intravenous injection of STZ on blood glu-
cose, body weight gain, glucose tolerance, and mechani-
cal hypernociception. After 12 h of food deprivation, rats
received an iv injection of 10 mM CB (pH 4.5, control rats)
or STZ at doses of 10, 20, or 40 mg/kg. Blood glucose
levels were evaluated 3 days later and then once a week
during the experiment by tail prick using a strip operated
reflectance meter (as described above). Body weight and
mechanical hypernociception were measured at different
times for 36 days after STZ or vehicle treatment (Figures 1
and 2). Mechanical hypernociception and blood glycemia
were not assessed on the same day to avoid the effect of
acute stress on the mechanical hypernociception meas-
urements. For the glucose tolerance test, additional ex-
perimental groups of rats fasted for 12 h received an iv
injection of 10 mM vehicle (CB, pH 4.5, equivalent volume)
or STZ (10, 20 or 40 mg/kg). Three days later, hyperglyce-
mia was observed only in rats treated with the higher dose
of STZ (40 mg/kg). The glucose tolerance test was con-
ducted 20 days after CB or STZ treatment as described
above.
Effect of insulin on mechanical hypernociception in-
duced by iv injection of STZ. To test the contribution of
hyperglycemia and/or insulinopenia to the genesis and
maintenance of mechanical hypernociception induced by
iv injection of STZ, rats were treated daily with insulin at
doses that completely prevented hyperglycemia. For this
purpose, after 12 h of food deprivation, rats received an iv
injection of 10 mM CB (pH 4.5, control rats) or 10 or 40 mg/
kg STZ in the morning (between 8:00-9:00 am). In the
afternoon of the same day, between 5:00 and 6:00 pm,
control rats and STZ-treated rats received a subcutaneous
injection of 200 μL saline (control groups) or 2 IU insulin (in
200 μL). Insulin or saline was administered twice a day (2
IU in the morning and 2 IU in the afternoon) 7 days a week
for 3 weeks. Glycemia was assessed daily in the morning
during the first and second week (except days 7 and 14) to
adapt insulin doses. During the third week, the blood
glucose measurement was performed in the morning be-
fore saline or insulin treatment on a day different day from
that of mechanical hypernociception assessment. Mechan-
ical hypernociception was evaluated on days 7, 14, 16, 18,
and 21 after STZ or CB treatment in the afternoon (be-
tween 1:00 and 4:00 pm).
Hypernociceptive and edematogenic effects of ipl in-
jection of STZ. This set of experiments investigated the
hypernociceptive and edematogenic properties of ipl injec-
tion of STZ. Rats received an ipl injection of 10 mM CB (pH
7.0; 100 μL) or STZ (30, 100, or 300 μg/paw, in 100 μL) and
mechanical hypernociception was evaluated 1, 2, 3, 5, 7,
8, and 24 h later. In the same rats, paw edema was
assessed immediately after the mechanical hypernocicep-
tion measurements 1, 3, and 5 h after ipl injection of STZ or
CB. Blood glucose levels were measured 8 h after CB or
STZ administration as described above.
Effect of dexamethasone on the mechanical hyperno-
ciception and paw edema induced by ipl injection of STZ.
Another set of experiments was performed to determine
whether the mechanical hypernociception and paw edema
induced by local administration of STZ was dependent on
the release of inflammatory mediators. Saline (control
groups, 0.25 mL/200 g, sc) or dexamethasone (1 mg/kg,
sc) was injected 1 h prior to STZ (100 μg/paw, in 100 μL) or
CB treatment (10 mM, pH 7.0; 100 μL). The intensity of
hypernociception was measured 1, 3, and 5 h later. The
effect of dexamethasone treatment on STZ-induced paw
edema was evaluated in the same experimental groups
right after the assessment of mechanical hypernocicep-
tion. Dexamethasone treatment per se did not affect the
basal latencies in the mechanical nociceptive test or the
paw volume in CB-treated rats (data not shown).
Effect of local or systemic treatment with morphine on
mechanical hypernociception induced by iv or ipl injection
of STZ. Next, we investigated whether the nociceptive
behavior induced by iv or ipl STZ treatment was inhibited
by morphine. In the first experiment, rats fasted for 12 h
received an iv injection of CB (10 mM, pH 4.5) or STZ (10
or 40 mg/kg). Three days later, hyperglycemia was con-
firmed only in rats treated with STZ at the dose of 40 mg/kg.
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As previously observed, iv injection of STZ at doses of 10
or 40 mg/kg induced a significant mechanical hypernocice-
ption 2 weeks after injection (data not shown). The effect of
local or systemic treatment with morphine on this process
was investigated 31 days after CB or STZ treatment.
Briefly, on day 31 the mechanical nociceptive latencies
were evaluated before (zero time) and 0.5, 1, and 3 h after
morphine (8 μg/paw or 2 mg/kg, sc) or saline (equivalent
volume) treatment. Next, we evaluated the effect of mor-
phine treatment on the mechanical hypernociception in-
duced by ipl injection of STZ. For this, mechanical hyper-
nociception was evaluated before the treatments (basal
latencies) and then saline (equivalent volume) or morphine
(8 μg/paw or 2 mg/kg, sc) was administered. Thirty minutes
later, rats received an ipl injection of CB (10 mM, pH 7.0;
100 μL) or STZ (100 μg/paw). Mechanical hypernocicep-
tion was assessed again 1, 3, 5 and 7 h after CB or STZ
treatment. In both experiments, morphine treatment did
not modify the reaction time in CB-treated control rats
(data not shown).
Statistical analysis
Data are reported as means ± SEM for groups of 6-7
animals and are representative of two independent experi-
ments. The Student t-test for unpaired groups was used,
and one-way ANOVA followed by the Bonferroni test was
used to determine differences between the experimental
groups. A repeated measure ANOVA was used to com-
pare the groups and doses at all times (curves). The level
of significance was set at P < 0.05.
Results
The data in Figure 1 (panels A and B) show that iv
injection of STZ at doses of 10 or 20 mg/kg neither induced
an increase of blood glycemia nor a loss of body weight
Figure 1. Blood glucose, body weight and glucose tolerance test
in streptozotocin (STZ)-treated rats. Rats received an iv injection
of citrate buffer (CB; control group; 10 mM, pH 4.5, equivalent
volume) or STZ (10, 20 or 40 mg/kg). Metabolic parameters
(blood glycemia, panel A and body weight, panel B) were evalu-
ated at the indicated time (weeks or days) after CB or STZ
treatments. The glucose tolerance test was performed 20 days
after vehicle or STZ treatments (panel C) to determine the time
course development of the pre-diabetes state. After 12 h of food
deprivation, blood glucose was measured immediately before iv
administration of 0.5 g/kg glucose solution (time 0) and then
again 7.5, 15, 30, and 60 min later. Only STZ-treated (40 mg/kg)
rats were glucose tolerant. Data are reported as means ± SEM
for groups of 6-7 rats. *P < 0.05 compared to CB- or STZ- (10 or
20 mg/kg) treated rats (ANOVA followed by the Bonferroni t-test);
#P < 0.05 compared to pre-glucose overload levels (panel C).
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compared to CB-treated rats. In contrast, the injection of
40 mg/kg STZ induced a significant increase of blood
glycemia and a reduced weight gain when compared to
citrate buffer-treated control rats (P < 0.05).
In the glucose tolerance test (Figure 1, panel C), all rats
displayed significantly higher blood glucose levels 7.5 min
after the glucose injection compared to values obtained
before the glucose overload (P < 0.05). Treatment with
STZ at the dose of 40 mg/kg, but not 10 or 20 mg/kg,
induced a significant difference in blood glucose uptake
after glucose challenge when compared to CB-treated
rats. Only the experimental group treated with 40 mg/kg
STZ maintained significantly higher blood glucose levels
compared to basal values one hour after the glucose
overload (Figure 1, panel C).
Intravenous administration of STZ induced mechanical
hypernociception that was independent of
hyperglycemia
In addition to the fact that rats treated with 40 mg/kg
STZ displayed hyperglycemia, the iv injection of STZ at all
doses used (10, 20, or 40 mg/kg) induced mechanical
hypernociception in the rat hind paw when compared to
CB-treated rats (P < 0.05; Figure 2). The mechanical
hypernociception started on day 19, reached a peak on
day 23 and was maintained until day 36 when the experi-
ment was terminated. Intravenous injections of STZ (10,
20, or 40 mg/kg) induced mechanical hypernociception in
both hind paws of the same magnitude and with the same
time course (data not shown).
Prevention of hyperglycemia by chronic insulin
treatment did not inhibit STZ-induced mechanical
hypernociception
As shown in Figure 3, daily treatment with insulin, but not
saline, completely prevented the development of hypergly-
cemia induced by iv administration of STZ at the dose of 40
mg/kg. However, insulin treatment did not alter the course of
mechanical hypernociception induced by STZ at doses of
either 10 or 40 mg/kg. Additionally, this daily dose of insulin
significantly reduced glycemia in normoglycemic experi-
mental groups treated with CB or STZ (10 mg/kg) during the
experimental period (Figure 3). Interestingly, in this experi-
ment, mechanical hypernociception developed earlier com-
pared to experiment 1 (Figure 2), i.e., it started on day 14 and
reached a peak on day 16. This discrepancy could be
attributed to different potency of the STZ lots.
Mechanical hypernociception and paw edema induced
by local administration of STZ
As shown in Figure 4 (panel A), ipl injection of 30, 100
Figure 2. Mechanical hypernociception induced by iv adminis-
tration of streptozotocin (STZ). Mechanical hypernociception
was evaluated on the days indicated after iv administration of
vehicle (control group; citrate buffer, 10 mM, pH 4.5, equivalent
volume) or STZ (10, 20 or 40 mg/kg). Data are reported as
means ± SEM for groups of 6 rats. *P < 0.05 compared to citrate
buffer-treated rats (ANOVA followed by the Bonferroni t-test).
or 300 μg/paw STZ induced ipsilateral mechanical hyper-
nociception in a dose-dependent fashion. The mechanical
hypernociception induced by ipl injection of STZ was sta-
tistically significant 1 h after injection, attained a peak 3 h
later, maintained a significant level until 8 h (P < 0.05), and
was not demonstrable 24 h post-injection. As expected,
none of the ipl STZ-treated rats displayed a significant
increase of blood glucose levels when they were evalu-
ated 8 h post-injection (means ± SEM of 6 rats per group,
in mg/dL; CB: 83.60 ± 2.27; 30 μg STZ: 89.79 ± 7.08; 100
μg STZ: 89.07 ± 6.07 and 300 μg STZ: 104.83 ± 5.67).
Intraplantar injection of STZ at doses of 100 and 300 μg/
paw, but not at 30 μg/paw, induced a significant increase in
paw edema when evaluated 1, 3 or 5 h post-injection
(Figure 4, panel B). The increase of paw volume was
significantly higher than that observed in CB-treated rats 1
h after STZ injection, reached a peak at 3 h and declined
thereafter (Figure 4, panel B).
Dexamethasone prevented the edema but not the
mechanical hypernociception induced by ipl
administration of STZ
Pre-treatment with dexamethasone (1 mg/kg, sc, 1 h
before STZ) did not alter the nociceptive effect of STZ (100
μg/paw in 100 μL; Figure 5, panel A). To check the effec-
tiveness of the doses of dexamethasone used in this
experiment, paw edema was evaluated in the same ex-
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perimental groups. Intraplantar injection of STZ (100 μg/
paw in 100 μL) induced a significant increase of paw
volume when compared to CB-treated rats (P < 0.05,
Figure 5, panel B) that was completely prevented by pre-
Figure 3. Mechanical hypernociception induced by streptozotocin (STZ) was not prevented by daily insulin treatment. Panel A,
Mechanical hypernociception was evaluated on the days indicated after iv administration of vehicle (control group; citrate buffer, 10
mM, pH 4.5, equivalent volume) or STZ (10 or 40 mg/kg). Insulin or saline (equivalent volume) was administered subcutaneously
twice (2 IU in the morning between 8:00 and 9:00 am, and 2 IU in the afternoon between 5:00 and 6:00 pm). Panel B, Glycemia was
determined in the morning during the 1st, 2nd or 3rd week after citrate buffer or STZ treatment (10 or 40 mg/kg). Data are reported as
means ± SEM for groups of 6 rats. *P < 0.05 compared to citrate-buffer saline and daily saline-treated rats; +P < 0.05 compared to
daily saline-treated rats (ANOVA followed by the Bonferroni t-test).
Figure 4. Mechanical hypernociception and paw edema induced by local ipl administration of streptozotocin (STZ). Mechanical
hypernociception (panel A) and paw edema (panel B) were evaluated at the indicated hours after ipl administration of vehicle (control
group; citrate buffer, 10 mM, pH 7.0; 100 μL/paw) or STZ (30, 100, or 300 μg/paw). Data are reported as means ± SEM for groups of
6 rats. *P < 0.05 compared to citrate buffer-treated rats (ANOVA followed by the Bonferroni t-test).
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treatment with dexamethasone.
Mechanical hypernociception induced by iv or ipl
injection of STZ shows different sensitivity to morphine
treatment
Morphine (2 mg/kg, sc) administered 31 days after iv
STZ injection or 30 min before ipl injection of STZ signifi-
cantly inhibited the mechanical hypernociception induced
by all STZ doses (Figure 6, panels A and B). In rats treated
with iv STZ, the anti-hypernociceptive effect induced by
systemic morphine was significant at 0.5 h and 1 h, return-
ing to the saline control levels 3 h after injection (Figure 6,
Figure 5. Effect of dexamethasone on hypernociception and edema induced by ipl administration of streptozotocin (STZ). Saline
(control groups, sc ; 0.25 mL/200 g) or dexamethasone (1 mg/kg, sc) was injected one hour before STZ treatment (100 μg/paw in 100
μL) and hypernociception (panel A) or edema (panel B) was measured 1, 3 and 5 h later. The dotted line indicates the paw volume of
control rats treated with citrate buffer (10 mM, pH 7.0; 100 μL/paw). Data are reported as means ± SEM for groups of 6 rats. *P < 0.05
compared to saline-treated rats (ANOVA followed by the Bonferroni t-test).
Figure 6. Effect of morphine on mechanical hypernociception induced by streptozotocin (STZ). Panel A, Saline (control groups,
equivalent volume) or morphine (2 mg/kg, sc or 8 μg/paw, ipl ) was injected 31 days after STZ treatment (10 or 40 mg/kg). Mechanical
hypernociception was measured before the treatments (time 0 h) and 0.5, 1, and 3 h later. The dotted line indicates the mean reaction
time of citrate buffer-treated rats. Panel B, Saline (control group, equivalent volume) or morphine (2 mg/kg, sc ; 8 μg/paw, ipl ) was
injected 30 min before STZ treatment (100 μg/paw). Mechanical hypernociception was evaluated 1, 3, 5, and 7 h after STZ injection. Data
are reported as means ± SEM for groups of 6 rats. *P < 0.05 compared to saline-treated rats (ANOVA followed by the Bonferroni t-test).
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panel A). However, in rats treated with ipl STZ, the mor-
phine effect remained significantly different from saline-
treated rats until 5 h after STZ injection (P < 0.05; Figure 6,
panel B), returning to saline control levels at 7 h. In con-
trast, morphine (8 μg/paw, ipl ) significantly inhibited the
mechanical hypernociception induced by ipl, but not by iv
treatment with STZ (100 μg/paw and 10 or 40 mg/kg,
respectively; Figure 6, panels A and B). The effect of ipl
treatment with morphine on mechanical hypernociception
induced by ipl injection of STZ (100 μg/paw) was signifi-
cantly different from saline-treated rats at a time of 1 and 3
h, returning to the saline control levels 5 h after injection
(Figure 6, panel B).
Discussion
Hypernociception induced by systemic STZ adminis-
tration has been widely used as an animal model of dia-
betic neuropathy. It has been demonstrated that STZ in-
duces rapid necrosis of pancreatic β-cells by activating
immune mechanisms, DNA alkylation and/or direct nitric
oxide generation (26,27). Fragmentation of nuclear DNA in
pancreatic β-cells is also important for the induction of
diabetes (28). Since some rats fail to develop hyperglyce-
mia after systemic administration of STZ, the exclusion of
these rats is almost imperative in studies involving hyper-
nociception associated with diabetes. Although this proce-
dure is in accordance with the paradigm of the hypernoci-
ception associated with diabetes, the observation that
STZ-induced hypernociception in rats is not always asso-
ciated with hyperglycemia (24) suggests that STZ can
induce hypernociception, at least in part, by a mechanism
other than hyperglycemia. In fact, in the present study, we
demonstrated that systemic, as well as local (ipl ) adminis-
tration of non-hyperglycemic doses of STZ, induces me-
chanical hypernociception (Figures 2 and 4). In this study,
the classical dose of 40 mg/kg of STZ induced hyperglyce-
mia in all injected rats. In contrast, the doses of 10 or 20
mg/kg did not cause hyperglycemia in any of the injected
rats (Figure 1, panel A). However, all STZ-challenged rats
(hyperglycemic or not) showed a marked decrease in
mechanical withdrawal threshold in both hind paws during
the two weeks following treatment. In addition, there were
no significant differences in time course or magnitude of
hypernociception between hyperglycemic and non-hyper-
glycemic rats (Figure 2). The time course of hypernocicep-
tion induced by systemic administration of STZ in the
present study did not differ from that reported in previous
studies (8-15). Our findings suggest that a factor other than
hyperglycemia is involved in STZ-induced mechanical hy-
pernociception. Although it has been proposed that the
general health deterioration caused by STZ could influ-
ence the mechanical nociceptive threshold (29), our study
showed that hypernociception induced by STZ was not
associated with reduced weight gain (Figure 1, panel B) or
general poor health.
It has been proposed that idiopathic sensory neuropa-
thies can be associated with undiagnosed abnormal glu-
cose metabolism and that the steady-state blood glucose
concentration is not always a good indicator of diabetic
injury (30). To exclude the influence of a pre-diabetes
status on the mechanical hypernociception induced by
STZ, a glucose tolerance test was performed in all STZ-
treated rats, but only rats treated with 40 mg/kg of STZ
demonstrated glucose tolerance.
Although our first set of experiments demonstrated that
STZ-induced hypernociception was not associated with
the impairment of glucose metabolism, it has been sug-
gested that insulinopenia rather than hyperglycemia could
be involved in the neuropathy of type 2 diabetes (31).
Since normoglycemic STZ-treated rats without glucose
tolerance can show a marked reduction in blood serum
insulin levels (24), in this study, rats were treated daily with
4 IU insulin. This treatment completely prevented hyper-
glycemia, but in contrast to previous studies (6,7,12,20) it
did not prevent the development of mechanical hypernoci-
ception induced by STZ. This incongruent data may be
explained by the different experimental protocols adopted
or doses utilized.
Taken together, these data strongly suggest that the
genesis of the mechanical hypernociception induced by
STZ may not be associated only with diabetes. Although
the mechanism underlying the STZ-induced mechanical
hypernociception remains unclear, we demonstrated in
this study that local administration of STZ in the subcuta-
neous plantar tissue induced mechanical hypernocicep-
tion in a dose-dependent manner only in the injected paw.
However, the time courses of local and systemic adminis-
tration of STZ were not the same. While systemic STZ-
induced hypernociception started during the second week
and lasted more than 36 days, the hypernociception in-
duced by local administration of STZ was resolved within
24 h. Furthermore, complementary experiments demon-
strated that 1) rats treated with an iv injection of STZ did not
display mechanical hypernociception soon after treatment
(at 1, 3, 5, 7, or 24 h post-treatment; data not shown) and
2) ipl injection of STZ did not induce a protracted mechan-
ical hypernociception (7, 14, 16, or 19 days post-treatment;
data not shown). It is possible that STZ may differently
sensitize the peripheral afferent nociceptors and the cen-
tral nociceptive neurons, although the hyperglycemia state
was not required in either case. In addition, local subcuta-
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neous morphine inhibited the hypernociception induced by
local, but not systemic treatment with STZ (Figure 6, pan-
els A and B). The reduction of the hypernociception medi-
ated by local morphine indicates that STZ may preferen-
tially affect the nociceptors associated with C-fibers given
that peripheral opioid receptors are more often expressed
in small diameter fibers (32,33). Since small diameter
primary afferent fibers are the class of nociceptors pre-
dominantly involved in inflammatory pain, it has been
plausibly hypothesized that the hypernociception induced
by STZ could be dependent on the release of inflammatory
mediators. Indeed, local subcutaneous administration of
STZ has an edematogenic effect although it was signifi-
cantly less severe when compared to edema induced by a
typical inflammatory stimulus, such as carrageenan.
In the present study, we demonstrated that pre-treat-
ment with dexamethasone completely prevented the STZ-
induced edema, but did not inhibit the course of mechani-
cal hypernociception. It has been proposed that glucocor-
ticoids such as dexamethasone have an additional biologi-
cal activity on the phospholipase pathway, i.e., the capac-
ity to stimulate production of inhibitors of kappa B, which
bind to and inhibit nuclear factor kappa B (NF-κB), a
transcription factor that plays a central role in the induction
of a number of cytokine genes including tumor necrosis
factor α (TNF-α), interleukin (IL)-1β, IL-2, IL-3, IL-6, and IL-
8 (34,35). Several of these genes are also regulated by
another transcription factor, activator protein 1 (AP-1) (35),
which has a synergistic effect with NF-κB (36). The inhibi-
tion of the activities of both NF-κB and AP-1 by glucocorti-
coids provides additional mechanisms to explain the po-
tent anti-inflammatory and analgesic effects of these drugs
since the role of cytokines in the genesis of inflammatory
mechanical hypernociception has been well established
(37). Consistent with the role of TNF-α and IL-1β in inflam-
matory hypernociception, paw skin concentrations of these
cytokines increase markedly after injection of carrageenan
(38). In neuropathic pain models, IL-1, TNF-α and IL-6
make important contributions to mechanical hypernoci-
ception after sciatic nerve constriction (39). However, the
plantar cutaneous tissue challenged with STZ, although
sensitized to mechanical stimuli, presented a negative
immunoreactivity to IL-1β, IL-6 or cytokine-induced neutro-
phil chemoattractant-1 (data not shown).
Indeed, morphine is effective in restoring the reduction
of reaction time, which demonstrates a nociceptive char-
acter of the behavioral response, as induced by local
administration of STZ. However, further studies are needed
to better characterize the mechanism by which STZ in-
duces mechanical sensitization of the sensory neurons.
The present data suggest that systemic administration
of STZ, a universal chemical agent used to induce experi-
mental diabetes, induces mechanical hypernociception
that does not seem to be exclusively dependent on hyper-
glycemia. This may limit its usefulness as a model of
diabetic neuropathy1.
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